Somatostatin Receptor Splicing Variant
Adult
Aged
Alternative Splicing
Brain Neoplasms
/ genetics
Cell Line, Tumor
Cell Movement
Cell Proliferation
Cell Survival
Drug Resistance, Neoplasm
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Glioblastoma
/ genetics
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Prognosis
Receptors, Somatostatin
/ genetics
Signal Transduction
Somatostatin
/ analogs & derivatives
Up-Regulation
glioblastoma
somatostatin analogs
somatostatin receptor
splicing variant
sst5TMD4
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
20 Jan 2022
20 Jan 2022
Historique:
received:
07
12
2021
revised:
29
12
2021
accepted:
17
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Glioblastoma (GBM) is the most malignant and lethal brain tumor. Current standard treatment consists of surgery followed by radiotherapy/chemotherapy; however, this is only a palliative approach with a mean post-operative survival of scarcely ~12-15 months. Thus, the identification of novel therapeutic targets to treat this devastating pathology is urgently needed. In this context, the truncated splicing variant of the somatostatin receptor subtype 5 (sst5TMD4), which is produced by aberrant alternative splicing, has been demonstrated to be overexpressed and associated with increased aggressiveness features in several tumors. However, the presence, functional role, and associated molecular mechanisms of sst5TMD4 in GBM have not been yet explored. Therefore, we performed a comprehensive analysis to characterize the expression and pathophysiological role of sst5TMD4 in human GBM. sst5TMD4 was significantly overexpressed (at mRNA and protein levels) in human GBM tissue compared to non-tumor (control) brain tissue. Remarkably,
Identifiants
pubmed: 35163067
pii: ijms23031143
doi: 10.3390/ijms23031143
pmc: PMC8835306
pii:
doi:
Substances chimiques
Receptors, Somatostatin
0
Somatostatin
51110-01-1
somatostatin receptor 5
8X85ZJG6XJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Science, Innovation and Universities
ID : PID2019-105564RB-I00, PID2019-105201RB-I00; Predoctoral contracts: FPU16-05059, FPU20-03954, FPU18-06009
Organisme : Instituto de Salud Carlos III
ID : CD19/00255
Organisme : Regional Government of Andalusia
ID : BIO-0139; P20_00442; PEER-0048-2020
Organisme : Instituto de Salud Carlos III
ID : CIBERobn
Références
Endocrine. 2015 Nov;50(2):442-52
pubmed: 25854304
Int J Cell Biol. 2013;2013:463786
pubmed: 24101931
Int J Mol Sci. 2019 Jun 22;20(12):
pubmed: 31234481
CNS Oncol. 2016 Jul;5(3):145-57
pubmed: 27230974
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
FASEB J. 2017 Nov;31(11):4682-4696
pubmed: 28705809
Sci Rep. 2019 Jan 14;9(1):85
pubmed: 30643153
Oncotarget. 2017 Jul 25;8(30):49123-49132
pubmed: 28467778
Oncotarget. 2016 Feb 9;7(6):6593-608
pubmed: 26673010
Adv Drug Deliv Rev. 2021 Apr;171:108-138
pubmed: 33486006
CA Cancer J Clin. 2020 Jul;70(4):299-312
pubmed: 32478924
Aging Male. 2020 Dec;23(5):440-446
pubmed: 30295140
J Clin Endocrinol Metab. 2010 May;95(5):2497-502
pubmed: 20233783
J Neurooncol. 1997 Dec;35(3):353-64
pubmed: 9440032
Int J Mol Sci. 2020 Mar 28;21(7):
pubmed: 32231094
Nat Rev Clin Oncol. 2020 Aug;17(8):457-474
pubmed: 32303702
Oncotarget. 2016 Sep 13;7(37):60110-60122
pubmed: 27507050
Minerva Endocrinol. 2019 Jun;44(2):109-128
pubmed: 30650942
Semin Cancer Biol. 2003 Feb;13(1):41-7
pubmed: 12507555
Clin Cancer Res. 2013 Feb 15;19(4):764-72
pubmed: 23209033
Oncogene. 2012 Apr 19;31(16):2049-61
pubmed: 21927030
Ann N Y Acad Sci. 2011 Mar;1220:6-15
pubmed: 21388399
Nature. 2008 Oct 23;455(7216):1129-33
pubmed: 18948956
Cancer Rep (Hoboken). 2019 Dec;2(6):e1216
pubmed: 32721125
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Oncogene. 2004 Apr 12;23(16):2838-49
pubmed: 15077147
Pharmacol Ther. 2015 Aug;152:98-110
pubmed: 25956467
Cancer Lett. 2015 Apr 10;359(2):299-306
pubmed: 25637790
J Physiol Paris. 2000 May-Aug;94(3-4):251-8
pubmed: 11088002
J Neurooncol. 2013 Aug;114(1):1-11
pubmed: 23673515
Endocr Relat Cancer. 2016 Dec;23(12):R551-R566
pubmed: 27697899
Transl Res. 2019 Sep;211:147-160
pubmed: 30904441
Artif Intell Med. 2020 Aug;108:101950
pubmed: 32972670
CA Cancer J Clin. 2021 Sep;71(5):381-406
pubmed: 34427324
Brain Sci. 2019 Dec 26;10(1):
pubmed: 31888004
Genome Biol. 2021 Jan 26;22(1):48
pubmed: 33499924
Neuro Oncol. 2016 Mar;18(3):329-39
pubmed: 26534766
Growth Horm IGF Res. 2015 Oct;25(5):262-7
pubmed: 26188991
Mol Cell. 2019 Oct 3;76(1):148-162.e7
pubmed: 31447391
J Neurosurg. 2017 Sep;127(3):660-669
pubmed: 27982767
Cancers (Basel). 2019 Sep 26;11(10):
pubmed: 31561558
J Clin Endocrinol Metab. 2009 Jul;94(7):2634-43
pubmed: 19401364
PLoS One. 2014 Jan 21;9(1):e85527
pubmed: 24465589
Adv Sci (Weinh). 2020 Mar 12;7(9):1902971
pubmed: 32382477
Cell Death Dis. 2021 Apr 30;12(5):433
pubmed: 33931589
Pediatr Hematol Oncol. 2009 Jul-Aug;26(5):363-74
pubmed: 19579083
J Neuropathol Exp Neurol. 2004 Jan;63(1):13-9
pubmed: 14748557
Trends Endocrinol Metab. 2004 Sep;15(7):300-10
pubmed: 15350601
Ann Oncol. 2001;12 Suppl 2:S131-4
pubmed: 11762340
Cancer Res. 1994 Nov 15;54(22):5895-901
pubmed: 7954420
Clin Cancer Res. 2000 Feb;6(2):709-17
pubmed: 10690557
EBioMedicine. 2020 Jan;51:102547
pubmed: 31902674
Pharmacol Rev. 2018 Oct;70(4):763-835
pubmed: 30232095
Brain. 2020 Dec 5;143(11):3273-3293
pubmed: 33141183
Cancer Res. 2009 Sep 1;69(17):6790-8
pubmed: 19706761
Cancer Treat Rev. 2004 Apr;30(2):193-204
pubmed: 15023437